Guzzardi Giuseppe, Galbiati Andrea, Stanca Carmelo, Del Sette Bruno, Paladini Andrea, Cossandi Christian, Carriero Alessandro
Department of Interventional and Neurointerventional Radiology, University Hospital "Maggiore della Carità", Novara, Italy.
Division of Neurosurgery, University Hospital "Maggiore della Carità", Novara, Italy.
Interv Neuroradiol. 2020 Oct;26(5):525-531. doi: 10.1177/1591019920950878. Epub 2020 Aug 16.
The use of flow diverter stent (FDS) has limitations in cases of subarachnoid haemorrhage caused by ruptured aneurysm, due to the need for double antiplatelet therapy and the delay in the aneurysm occluding. The p48 MW and the p64 MW (Phenox) are available with Hydrophilic Polymer Coating (HPC), that reduces the risk of thrombus formation. Purpose of this study is to evaluate the safety and efficacy of p48 and p64 MW HPC with single antiplatelet therapy for the acute treatment of ruptured aneurysm.
We retrospectively evaluated all patients treated for acutely ruptured aneurysms with a p48 MW HPC or p64 MW HPC from October 2019 to April 2020 using single antiplatelet therapy. For each patient, we considered demographic and aneurysm-related data, clinical presentation, size and location of the implanted flow diverter stent, intra- and post-procedural complications, aneurysm occlusion.
Seven patients were included. The ruptured aneurysms were four saccular, two blister-like and one dissecting, six in the anterior and one in posterior circulation. No intraprocedural stent thrombosis and rebleeding was observed. In two cases the aneurysm is completely excluded, in one patient it was found only neck perfusion, in three cases there were mild reduction of the sac and in one case there was a persistent perfusion. No patients needed retreatment in this series.
In our experience, FDS HPC appears a potential treatment option in selected cases. Our study is limited by small population and short-term follow-up. We report our preliminary data, but further investigations are necessary.
由于需要双重抗血小板治疗以及动脉瘤闭塞延迟,血流导向支架(FDS)在破裂动脉瘤引起的蛛网膜下腔出血病例中的应用存在局限性。p48 MW和p64 MW(菲尼克斯)带有亲水性聚合物涂层(HPC),可降低血栓形成风险。本研究的目的是评估p48和p64 MW HPC在单药抗血小板治疗急性破裂动脉瘤中的安全性和有效性。
我们回顾性评估了2019年10月至2020年4月期间使用单药抗血小板治疗,接受p48 MW HPC或p64 MW HPC治疗急性破裂动脉瘤的所有患者。对于每位患者,我们考虑了人口统计学和动脉瘤相关数据、临床表现、植入的血流导向支架的尺寸和位置、术中及术后并发症、动脉瘤闭塞情况。
纳入7例患者。破裂动脉瘤为4个囊状、2个水泡状和1个夹层动脉瘤,6个位于前循环,1个位于后循环。未观察到术中支架血栓形成和再出血。2例动脉瘤完全闭塞,1例仅发现颈部灌注,3例囊腔轻度缩小,1例持续灌注。本系列中无患者需要再次治疗。
根据我们的经验,FDS HPC在某些特定病例中似乎是一种潜在的治疗选择。我们的研究受限于样本量小和短期随访。我们报告了初步数据,但仍需要进一步研究。